CytoDyn (CYDY) to Release Earnings on Tuesday

Key Points

• Q3 2026 earnings will be released after the market closes on Tuesday, April 14, with analysts forecasting earnings of ($0.05) per share, and an earnings call scheduled for April 17 at 9:30 AM ET.
• CytoDyn last reported EPS of ($0.02) on January 9; the stock opened at $0.27 with a market capitalization of $344.06 million and a 52-week range of $0.19–$0.45.
• CytoDyn is a clinical-stage biotech whose lead candidate, leronlimab (PRO 140), targets the CCR5 receptor and is being developed for treatment-resistant HIV and metastatic triple-negative breast cancer among other indications.

CytoDyn (OTCMKTS:CYDY - Get Free Report) is expected to issue its Q3 2026 results after the market closes on Tuesday, April 14th. Analysts expect the company to announce earnings of ($0.05) per share for the quarter. Individuals can check the company's upcoming Q3 2026 earning summary page for the latest details on the call scheduled for Friday, April 17, 2026 at 9:30 AM ET.

CytoDyn (OTCMKTS:CYDY - Get Free Report) last issued its quarterly earnings data on Friday, January 9th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter.

CytoDyn Stock Up 0.5%

Shares of OTCMKTS:CYDY opened at $0.27 on Tuesday. The company has a market capitalization of $344.06 million, a price-to-earnings ratio of -8.93 and a beta of 1.17. The company has a 50 day moving average of $0.25 and a two-hundred day moving average of $0.27. CytoDyn has a 52-week low of $0.19 and a 52-week high of $0.45.

CytoDyn Company Profile

CytoDyn Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel immunotherapies. The company's lead product candidate, leronlimab (PRO 140), is a humanized monoclonal antibody designed to block the CCR5 receptor, which plays a critical role in HIV infection and certain cancer pathways. CytoDyn is advancing leronlimab through multiple clinical trials targeting indications such as treatment-resistant HIV, metastatic triple-negative breast cancer, and other oncology and inflammatory conditions.

In its pursuit of regulatory approvals, CytoDyn has conducted Phase II and Phase III studies of leronlimab in people living with HIV who have experienced virologic failure on existing therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.